[1]尉骁璐,孙建华,宫丽崑.单抗诱发性细胞因子释放综合征和体外细胞因子释放实验的研究进展[J].中国药理学通报,2018,(09):1185-1189.[doi:10.3969/j.issn.1001-1978.2018.09.001]
 YU Xiao-lu,SUN Jian-hua,GONG Li-kun.Research development of cytokine release syndrome induced by monoclonal antibody and cytokine release assays in vitro[J].Chinese Pharmacological Bulletin,2018,(09):1185-1189.[doi:10.3969/j.issn.1001-1978.2018.09.001]
点击复制

单抗诱发性细胞因子释放综合征和体外细胞因子释放实验的研究进展()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2018年09期
页码:
1185-1189
栏目:
讲座与综述
出版日期:
2018-09-26

文章信息/Info

Title:
Research development of cytokine release syndrome induced by monoclonal antibody and cytokine release assays in vitro
文章编号:
1001-1978(2018)09-1185-05
作者:
尉骁璐12孙建华12宫丽崑12
1.中国科学院大学药学院,北京 100049; 2.中科院上海药物研究所药物安全评价研究中心新药研究国家重点实验室,上海 201203
Author(s):
YU Xiao-lu12 SUN Jian-hua12 GONG Li-kun12
1.School of Pharmacy, University of Chinese Academy of Sciences, Beijing 100049,China; 2.State Key Laboratory of Drug Research, Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203,China
关键词:
单克隆抗体 细胞因子释放综合征 TGN1412 体外细胞因子释放实验 最低预期生物效应剂量 临床前安全性研究
Keywords:
monoclonal antibody cytokine-release syndrome TGN1412 cytokine release assay in vitro minimum anticipated biological effect level preclinical safety study
分类号:
R-05; R392.11; R392.12; R442.8
DOI:
10.3969/j.issn.1001-1978.2018.09.001
文献标志码:
A
摘要:
单克隆抗体引发的细胞因子释放综合征(CRS)具有发病迅速、危害严重、难以预测和控制等特点。近年来,建立可靠的体内动物模型和体外细胞因子释放实验(CRA)预测CRS的发生成为临床前安全性评价的研究热点。该文着重从CRA的适用对象、方法设计考虑因素、方法优化等方面进行综述,为CRA预测平台的优化提供建议。
Abstract:
Cytokine-release syndrome(CRS)triggered by monoclonal antibodies(mAbs)is characterized by rapid onset and severe damage, and difficulty in prediction and control.Recent years,it has been a research focus on establishing a reliable animal model in vivo and cytokine release assay(CRA)in vitro to predict CRS for preclinical safety evaluation. In this paper we summarize matters related to CRA applicable objects, considerations of method design and method optimization, aiming to provide suggestions for the optimization of CRA prediction platform.

参考文献/References:

[1] 阿丽塔, 穆 鑫, 唐小利, 等.1984~2014年治疗性生物药物发展历程及展望[J].中国药理学通报, 2015, 31(10):1356-62. [1] Aa L T, Mu X, Tang X L, et al. The development and prospect of therapeutic bio-drugs in the past 1984~2014 years [J]. Chin Pharmacol Bull, 2015, 31(10):1356-62.
[2] Pichler W J. Adverse side-effects to biological agents [J]. Allergy, 2006, 61(8):912-20.
[3] Lee D W, Gardner R, Porter D L, et al. Current concepts in the diagnosis and management of cytokine release syndrome [J]. Blood, 2014, 124(2):188-95.
[4] Tisoncik J R, Korth M J, Simmons C P, et al. Into the eye of the cytokine storm [J]. Microbiol Mol Biol Rev, 2012, 76(1):16-32.
[5] Peter J B, Ram A, Renold J C, et al. Momoclonal antibody-induced cytokine-release syndrome [J]. Expert Rev Clin Immunol, 2009, 5(5):499-521.
[6] Breslin S. Cytokine-release syndrome: overview and nursing implications [J]. Clin J Oncol Nurs, 2007, 11(1 Suppl):37-42.
[7] Suntharalingam G, Perry M R, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 [J]. N Engl J Med, 2006, 355(10):1018-28.
[8] Goldman M, Abramowicz D, De Pauw L, et al. OKT3-induced cytokine release attenuation by high-dose methylprednisolone [J]. Lancet, 1989, 2(8666):802-3.
[9] Wing M G, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16(FcgammaRIII)and CD11a/CD18(LFA-1)on NK cells [J]. J Clin Invest, 1996, 98(12):2819-26.
[10] Grimaldi C, Finco D, Fort M M, et al. Cytokine-release syndrome: cytokine release: a workshop proceedings on the state-of-the-science, current challenges and future directions [J]. Cytokine, 2016, 85:101-8.
[11] European Medicines Agency(EMEA). Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/07; 2007
[12] Finco D, Grimaldi C, Fort M, et al. Cytokine release assays: current practices and future directions [J]. Cytokine, 2014, 66(2):143-55.
[13] Vidal J M, Kawabata T T, Thorpe R, et al. In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop [J]. Cytokine, 2010, 51(2): 213-5.
[14] Romer P S, Berr S, Avota E, et al. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412 [J]. Blood, 2011, 118(26):6772-82.
[15] Vessillier S, Eastwood D, Fox B, et al. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials-whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm [J]. J Immunol Methods, 2015, 424:43-52.
[16] Wolf B, Morgan H, Krieg J, et al. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans [J]. Cytokine, 2012, 60(3):828-37.
[17] Stebbings R, Findlay L, Edwards C, et al. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics [J]. J Immunol, 2007, 179(5):3325-31.
[18] Findlay L, Eastwood D, Stebbings R, et al. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412 [J]. J Immunol Methods, 2010, 352(1-2):1-12.
[19] Reed D M, Paschalaki K E, Starke R D, et al. An autologous endothelial cell: peripheral blood mononuclear cell assay that detects cytokine storm responses to biologics [J]. FASEB J, 2015, 29(6):2595-602.
[20] Findlay L,Sharp G,Fox B,et al. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture [J]. Cytokine, 2011, 55(1):141-51.
[21] Chu J W, Sharom F J. Glycophorin a interacts with interleukin-2 and inhibits interleukin-2-dependent t-lymphocyte proliferation [J]. Cell Immunol, 1992, 145(2):223-239.
[22] D Eastwood L F, S Poole, C Bird, et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells [J]. Br J Pharmacol, 2010, 161(3):512-26.

相似文献/References:

[1]沈国栋,刘兢,宋礼华,等.抗ErbB2抗体曲妥珠单抗的耐药机制与展望[J].中国药理学通报,2010,(08):0.
 SHEN Guo dong,LIU Jing,SONG Li hua,et al.Mechanism and prospect of resistance to antiErbB2 antibody trastuzumab[J].Chinese Pharmacological Bulletin,2010,(09):0.
[2]潘兰红,徐 萌,曾世彬,等.碱性成纤维细胞生长因子单克隆抗体在小鼠体内药代动力学研究[J].中国药理学通报,2011,(11):1582.
 PAN Lan-hong,XUMeng,ZENG Shi-bin,et al. Pharm acokinetics of basic fibroblast growth factor m onoclonal antibody inm ice[J].Chinese Pharmacological Bulletin,2011,(09):1582.
[3]郭建军,王丽丽,张 琪,等.单克隆抗体药物的药代动力学研究进展[J].中国药理学通报,2016,(02):172.[doi:10.3969/j.issn.1001-1978.2016.02.006]
 GUO Jian-jun,WANG Li-li,ZHANG Qi,et al.Progress on pharmacokinetic studies of therapeutic monoclonal antibodies[J].Chinese Pharmacological Bulletin,2016,(09):172.[doi:10.3969/j.issn.1001-1978.2016.02.006]

备注/Memo

备注/Memo:
收稿日期:2018-03-16,修回日期:2018-04-28
基金项目:国家科技部“重大新药创制”科技重大专项(No 2015ZX09501007,2017ZX09302008-013); 中科院药物所创新研究院自主部署项目(No. CASIMM0120163004)
作者简介:尉骁璐(1993- ),女,博士生,研究方向:药理学,E-mail: xlyu@cdser.simm.ac.cn;
宫丽崑(1972-),女,博士,研究员,博士生导师,研究方向:药理毒理学,通讯作者,E-mail: lkgong@cdser.simm.ac.cn
更新日期/Last Update: 2018-08-26